New radioactive cocktail shows promise for tough prostate cancers
NCT ID NCT03939689
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 30 times
Summary
This study tested a radioactive drug (I-131-1095) plus a standard hormone therapy (enzalutamide) in 120 men with advanced prostate cancer that had stopped responding to another treatment (abiraterone). The goal was to see if the combination could shrink tumors and lower PSA levels more than enzalutamide alone. While the treatment aims to control the disease, it is not a cure, and ongoing management is still needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Hospitalier Del' Universite de Montreal
Montreal, Quebec, Canada
-
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, Canada
-
Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
-
City of Hope
Duarte, California, 91010, United States
-
Hoag Family Cancer Institute
Newport Beach, California, 92663, United States
-
Jewish General Hospital
Montreal, Quebec, Canada
-
LifeSpan Cancer Institute
Providence, Rhode Island, 09206, United States
-
London Health Sciences Centre
Toronto, Ontario, Canada
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Medstar Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
Tulane Medical School
New Orleans, Louisiana, 70112, United States
-
UCLA
Los Angeles, California, 90095-7370, United States
-
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, Canada
-
University of Iowa
Iowa City, Iowa, 52242, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Virginia Cancer Center
Charlottesville, Virginia, 22908, United States
-
University of Washington - Seattle Cancer Care Alliance
Seattle, Washington, 98109, United States
-
VA Greater Los Angeles Healthcare System
Los Angeles, California, 90073, United States
-
VA Palo Alto Healthcare System
Palo Alto, California, 94303, United States
-
Virginia Mason Medical Center
Seattle, Washington, 98101, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.